CVS Health (CVS) Stock Forecast & Price Target

$62.84

+1.46 (+2.38%)

(As of 09/30/2024 ET)

CVS Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
10

Buy
11

Based on 21 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 10 have given a hold rating, and 11 have given a buy rating for CVS.

Consensus Price Target

$72.10
14.74% Upside

According to the 21 analysts' twelve-month price targets for CVS Health, the average price target is $72.10. The highest price target for CVS is $100.00, while the lowest price target for CVS is $59.00. The average price target represents a forecasted upside of 14.74% from the current price of $62.84.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

CVS Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	10 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$72.10	$73.24	$75.05	$95.28
Forecasted Upside	14.74% Upside	27.95% Upside	32.36% Upside	36.72% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Does Elon Musk control the U.S. gov’t? (Ad)

Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.

Watch this new documentary and you’ll discover what Elon knows,

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Retail/Wholesale Companies	S&P 500
Consensus Rating Score	2.52	2.49	2.50
Consensus Rating	Moderate Buy	Hold	Hold
Predicted Upside	14.74% Upside	37.48% Upside	6.15% Upside
News Sentiment Rating	Neutral News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Cantor Fitzgerald 3 of 5 stars	S. James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$62.00 ➝ $62.00	+6.13%
9/4/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$68.00 ➝ $68.00	+17.22%
8/12/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $61.00	+8.04%
8/9/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$64.00 ➝ $63.00	+10.24%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$65.00 ➝ $63.00	+8.85%
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$65.00 ➝ $62.00	+9.79%
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$101.00 ➝ $86.00	+53.54%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$61.00	+13.55%
5/8/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Graja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$100.00 ➝ $80.00	+44.85%
5/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$99.00 ➝ $59.00	+5.41%
5/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $77.00	+41.73%
5/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $74.00	+36.08%
5/2/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $66.00	+21.37%
5/2/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $72.00	+27.84%
5/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.53%
5/1/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/1/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$87.00 ➝ $60.00	+5.60%
3/15/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$93.00 ➝ $94.00	+21.75%
12/22/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$94.00	+19.56%
11/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$110.00 ➝ $100.00	+43.55%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$93.00 ➝ $80.00	+11.41%
9/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$80.00	+16.36%
8/17/2023	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $85.00	+14.34%
5/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $96.00	+35.82%
2/9/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$130.00 ➝ $143.00	+60.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:32 AM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 21, 2024. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. stock price is currently at $57.75, potentially offering a good entry point for investors looking for value.
CVS Health Co. has a moderate buy rating from analysts, indicating positive sentiment towards the company's future performance.
CVS Health Co. reported a solid quarterly earnings result, beating the consensus estimate and showcasing strong financial performance.
CVS Health Co. has a diversified business model operating in Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, reducing risk exposure.
CVS Health Co. has a healthy dividend yield of 4.61%, providing investors with a steady income stream.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

CVS Health Co. stock has a 1-year low of $52.77, indicating potential volatility in the stock price.
CVS Health Co. has a debt-to-equity ratio of 0.83, which may raise concerns about the company's financial leverage.
CVS Health Co. recently had its target price lowered by multiple financial institutions, suggesting a lack of consensus on the company's future prospects.
CVS Health Co. has a beta of 0.53, indicating lower volatility compared to the market, potentially limiting upside gains.
CVS Health Co. has a current ratio of 0.86 and a quick ratio of 0.66, which may raise liquidity concerns among investors.

CVS Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $72.10, with a high forecast of $100.00 and a low forecast of $59.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 10 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CVS shares.
: According to analysts, CVS Health's stock has a predicted upside of 14.74% based on their 12-month stock forecasts.
: CVS Health has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore ISI, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.
: Analysts like CVS Health more than other "retail/wholesale" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "retail/wholesale" companies is Hold. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Shedding light on a dark secret (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

This page (NYSE:CVS) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners